High-ASDAS group (n=45) | Low-ASDAS group (n=71) | p-value | |
---|---|---|---|
Age, years | 35.0 (30.2–40.4) | 33.1 (25.6–40.3) | 0.222 |
Male sex, | 40 (88.9) | 69 (97.2) | 0.068 |
Disease duration, years | 11.1 (6.1–15.3) | 9.8 (4.6–15.8) | 0.465 |
Follow-up duration, years | 6.4 (4.0–6.9) | 6.5 (4.6–7.2) | 0.289 |
HLA B27 positivity | 44 (97.8) | 71 (100) | 0.207 |
Peripheral joint involvement | 22 (48.9) | 30 (42.3) | 0.484 |
History of psoriasis | 1 (2.2) | 1 (1.4) | 0.751 |
History of uveitis | 13 (28.9) | 22 (31.0) | 0.811 |
mSASSS | 12.0 (6.0–26.7) | 8.0 (6.0–23.7) | 0.256 |
BASDAI | 3.0 ± 0.6 | 1.8 ± 0.8 | < 0.001 |
ASDAS-CRP | 2.5 ± 0.3 | 1.7 ± 0.2 | < 0.001 |
ESR, mm/hr | 5.0 (2.0–11.5) | 2.0 (2.0–5.0) | 0.003 |
Abnormal ESR | 7 (15.6) | 2 (2.8) | 0.012 |
CRP, mg/dL | 0.2 (0.2–0.3) | 0.2 (0.2–0.2) | 0.243 |
Abnormal CRP | 8 (17.8) | 1 (1.4) | 0.001 |
Initial BASDAI (0 month) | 6.7 ± 1.3 (n=45) | 6.7 ± 1.5 (n=71) | 0.768 |
Initial ASDAS-CRP (0 month) | 3.9 ± 0.8 (n=35) | 4.0 ± 1.0 (n=57) | 0.471 |
Initial ESR (0 month), mm/hr | 31.5 (17.8–55.0) (n=43) | 38.0 (21.0–76.0) (n=70) | 0.331 |
Initial CRP (0 month), mg/dL | 1.6 (0.9–3.4) (n=43) | 1.9 (0.2–4.7) (n=70) | 0.562 |
Follow-up BASDAI (9 months) | 2.9 ± 1.1 (n=45) | 2.3 ± 1.4 (n=71) | 0.007 |
Follow-up ASDAS-CRP (9 months) | 1.8 ± 0.6 (n=36) | 1.5 ± 0.7 (n=58) | 0.079 |
High ASDAS-CRP (9 months) | 10 (27.8%) | 8 (13.8%) | 0.094 |
Follow-up ESR (9 months), mm/hr | 5.0 (2.0–11.0) (n=39) | 2.0 (2.0–7.0) (n=64) | 0.299 |
Follow-up CRP (9 months), mg/dL | 0.2 (0.2–0.2) (n=39) | 0.2 (0.2–0.2) (n=65) | 0.795 |
Discontinuation of anti-TNF agent | 8 (17.8) | 5 (7.1) | 0.022 |
Lack/loss of efficacy | 7 (87.5) | 2 (40) | |
Clinical remission | 0 (0) | 3 (60) | |
Adverse event | 1 (12.5) | 0 (0) |